ClinicalTrials.gg
CompletedNCT04952896Updated Nov 2, 2022

Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease

An observational study in Synovial Diseases, Pigmented Villonodular Synovitis and Gout, sponsored by Peking University Third Hospital. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Peking University Third Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
350
Sex
All
01

Study summary

Through the high-throughput feature extraction of magnetic resonance images, the deep learning prediction model of joint synovial lesions is constructed used for the diagnosis, differential diagnosis and curative effect monitoring of joint synovial lesions.

Read the detailed description

The study applies magnetic resonance and deep learning (DL) to the diagnosis of joint synovial lesions, aims to have a more comprehensive understanding of the pathophysiology of the occurrence and development of joint synovial lesions. As a non-invasive imaging method to assess the condition of the disease, DL methods excavates the deep features contained in the image, quantifies the joint synovial lesions, and then gives more information to the clinician in the diagnosis and differential diagnosis of the joint synovial lesions, provide important information for the planning of individualized treatment plans for patients with joint synovial diseases.

02

Conditions studied

  • Synovial Diseases
  • Pigmented Villonodular Synovitis
  • Gout
  • Rheumatoid Arthritis

Keywords

  • pigmented villonodular synovitis
  • deep learning
  • knee synovitis
  • MRI
03

In context

Synovitis, Pigmented Villonodular

20 studies on the registry are indexed under Synovitis, Pigmented Villonodular; 2 are open to participants now.

Browse Synovitis, Pigmented Villonodular studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 752 studies on the registry; 273 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with joint synovial disease through radiological examination, arthroscopy or pathological biopsy of the joint, or whose clinical manifestations meet the diagnostic criteria of the American College of Rheumatology (ACR) for joint synovial disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with joint synovial disease through radiological examination, arthroscopy or pathological of the joint, or whose clinical manifestations meet the diagnostic criteria of the American College of Rheumatology (ACR) for joint synovial disease.
  2. Patients received pre-treatment MR.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received surgery, medication or other systemic treatment before standardized MRI scan.
  2. Poor image quality.
  3. Articular hemorrhage.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
350 participants (actual)
Patient registry
No

Groups and cohorts

  • Group of patients with pigmented villonodular synovitis

    Diagnosis confirmed by arthroscopic pathological biopsy.

    Diagnostic Test: Synovitis diagnosis

  • Group of patients with rheumatoid arthritis

    Diagnosis determined by clinical history, laboratory tests and arthroscopic pathology biopsy.

    Diagnostic Test: Synovitis diagnosis

  • Group of patients with gout

    Diagnosis was determined by laboratory tests, energy spectrum imaging and arthroscopic pathology biopsy.

    Diagnostic Test: Synovitis diagnosis

Interventions

  • Diagnostic testSynovitis diagnosis
06

What researchers measure

Primary outcomes

  1. Patient's diagnosis

    Type of synovitis disease in patients with a clear comprehensive diagnosis

    Time frame: 2019-2022

07

Study locations

1 site
  • Peking University third hospital
    Beijing, Please Select An Option Below 100089, China
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04952896
Responsible party
Sponsor
First posted
Jul 7, 2021
Start date
Jan 1, 2012
Primary completion
Mar 31, 2022
Completion
Oct 29, 2022
Last update
Nov 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion